About Omicia

Omicia is unlocking individualized medicine by translating data derived from whole-genome sequencing into actionable information for researchers and clinicians. The company maintains a comprehensive database of information about genetic variations related to health conditions and is pioneering new informatics approaches that enhance the power of predictive and preventive medicine.

Increasingly affordable production of genome sequence data is driving demand for tools and expertise in whole genome analysis to make use of this complex information in clinical settings. Omicia's report-based products and services aid researchers and clinicians in interpreting the most relevant information from personal genome sequences and their potential medical consequences.

We are currently applying our unique and powerful tools through collaborations with leading researchers and institutions. Our team of world-class scientists, physicians, and software engineers has extensive experience in the development and commercialization of technology-driven healthcare solutions. Omicia is funded with private investments and a series of Small Business Innovation Research (SBIR) grants from the National Institutes of Health. The company is based in the San Francisco Bay Area.

Read our Company History